Antitumor effect of cell therapy with mesenchymal stem cells on murine melanoma B16-F10

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMENEZES, Fernanda Carrilho de
dc.contributor.authorCABRAL, Laertty Garcia de Sousa
dc.contributor.authorPETRELLIS, Maria Carla
dc.contributor.authorFESTA NETO, Cyro
dc.contributor.authorMARIA, Durvanei Augusto
dc.date.accessioned2020-10-15T14:33:07Z
dc.date.available2020-10-15T14:33:07Z
dc.date.issued2020
dc.description.abstractIn this study, the antitumor and immunomodulatory effects of mesenchymal stem cells (MSC) obtained from bone marrow in the treatment of dorsal melanoma B16-F10. The MSC cells were obtained from the bone marrow of isogenic C57BL/6J mice, characterized and inoculated by two routes, intratumor (it) and intravenous (iv). The hematological profile, expression markers and receptors, phases of the cell cycle and mitochondrial electrical potential were evaluated by flow cytometry. The dorsal tumor mass showed a significant reduction after treatment by the two routes of administration with a significant effect by the intravenous route. MSC showed immunomodulatory potential and did not induce an increase in the markers involved in tumor control and progression. The number of cells in the sub-G1 phase increased significantly after treatments compared to the control group. The percentage of cells in phases GO/G1, S and G2/M decreased, with only the group (it) showing a significant reduction. The intratumor group showed a significant decrease in the G2/M phase. Treatment with MSC provided a significant decrease in the percentage of metabolically active tumor cells, demonstrating its intrinsic effect in the control of cell proliferation. Regarding the mechanism of cell death, MSCs modulated the expression of proteins involved in the regulation of the cell cycle, angiogenesis receptors and pro-apoptotic proteins by intrinsic and extrinsic routes. Therefore, the use of undifferentiated MSC, administered intratumor and intravenous is possibly a promising treatment for melanoma.eng
dc.description.indexMEDLINEeng
dc.description.sponsorshipCNPqNational Council for Scientific and Technological Development (CNPq) [306124/2015-7]
dc.identifier.citationBIOMEDICINE & PHARMACOTHERAPY, v.128, article ID 110294, 12p, 2020
dc.identifier.doi10.1016/j.biopha.2020.110294
dc.identifier.eissn1950-6007
dc.identifier.issn0753-3322
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/37721
dc.language.isoeng
dc.publisherELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIEReng
dc.relation.ispartofBiomedicine & Pharmacotherapy
dc.rightsopenAccesseng
dc.rights.holderCopyright ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIEReng
dc.subjectTumoreng
dc.subjectMelanomaeng
dc.subjectMesenchymal stem cellseng
dc.subjectImmunomodulatoryeng
dc.subjectApoptosiseng
dc.subject.othercutaneous melanomaeng
dc.subject.otherangiogenesiseng
dc.subject.otherdeliveryeng
dc.subject.otherstrategyeng
dc.subject.wosMedicine, Research & Experimentaleng
dc.subject.wosPharmacology & Pharmacyeng
dc.titleAntitumor effect of cell therapy with mesenchymal stem cells on murine melanoma B16-F10eng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalCABRAL, Laertty Garcia de Sousa:Butantan Inst, Mol Biol Lab, Av Dr Vital Brasil 1500, BR-05599000 Sao Paulo, Brazil
hcfmusp.author.externalPETRELLIS, Maria Carla:Butantan Inst, Mol Biol Lab, Av Dr Vital Brasil 1500, BR-05599000 Sao Paulo, Brazil
hcfmusp.author.externalMARIA, Durvanei Augusto:Butantan Inst, Mol Biol Lab, Av Dr Vital Brasil 1500, BR-05599000 Sao Paulo, Brazil
hcfmusp.citation.scopus3
hcfmusp.contributor.author-fmusphcFERNANDA CARRILHO DE MENEZES
hcfmusp.contributor.author-fmusphcCYRO FESTA NETO
hcfmusp.description.articlenumber110294
hcfmusp.description.volume128
hcfmusp.origemWOS
hcfmusp.origem.pubmed32485571
hcfmusp.origem.scopus2-s2.0-85085571633
hcfmusp.origem.wosWOS:000561739400007
hcfmusp.publisher.cityISSY-LES-MOULINEAUXeng
hcfmusp.publisher.countryFRANCEeng
hcfmusp.relation.referenceAbdi R, 2008, DIABETES, V57, P1759, DOI 10.2337/db08-0180eng
hcfmusp.relation.referenceAhn JO, 2015, ANTICANCER RES, V35, P159eng
hcfmusp.relation.referenceBao Q, 2012, STEM CELLS DEV, V21, P2355, DOI 10.1089/scd.2012.0060eng
hcfmusp.relation.referenceBarkholt L, 2013, CYTOTHERAPY, V15, P753, DOI 10.1016/j.jcyt.2013.03.005eng
hcfmusp.relation.referenceBEATTIE CW, 1988, SEMIN ONCOL, V15, P500eng
hcfmusp.relation.referenceBERNENGO MG, 1983, CANCER, V52, P1841, DOI 10.1002/1097-0142(19831115)52:10<1841::AID-CNCR2820521014>3.0.CO;2-Neng
hcfmusp.relation.referenceBolognia J.L., 2017, DERMATOLOGY E BOOKeng
hcfmusp.relation.referenceBydlowski Sergio P., 2009, Rev. Bras. Hematol. Hemoter., V31, P25eng
hcfmusp.relation.referenceCorcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood-2005-07-2657eng
hcfmusp.relation.referenceCorsten MF, 2008, LANCET ONCOL, V9, P376, DOI 10.1016/S1470-2045(08)70099-8eng
hcfmusp.relation.referenceebertinga Cherly Lee D., 2004, J DERMATOL, V31, P299eng
hcfmusp.relation.referenceEnnis WJ, 2013, ADV WOUND CARE, V2, P369, DOI 10.1089/wound.2013.0449eng
hcfmusp.relation.referenceFerrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669eng
hcfmusp.relation.referenceFuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7eng
hcfmusp.relation.referenceGhaedi M, 2011, J GENE MED, V13, P171, DOI 10.1002/jgm.1552eng
hcfmusp.relation.referenceGoncalves FD, 2014, WORLD J GASTROENTERO, V20, P18228, DOI 10.3748/wjg.v20.i48.18228eng
hcfmusp.relation.referenceJavan MR, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00840eng
hcfmusp.relation.referenceMahla Ranjeet Singh, 2016, INT J CELL BIOL, DOI [10.1155/2016/6940283, DOI 10.1155/2016/6940283]eng
hcfmusp.relation.referenceMartin FT, 2010, BREAST CANCER RES TR, V124, P317, DOI 10.1007/s10549-010-0734-1eng
hcfmusp.relation.referenceMirzaei H, 2016, CURR MED CHEM, V23, P455, DOI 10.2174/0929867323666151217122033eng
hcfmusp.relation.referenceNajafabadi MM, 2018, CELL J, V20, P19, DOI 10.22074/cellj.2018.4924eng
hcfmusp.relation.referenceNauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716eng
hcfmusp.relation.referenceRamdasi Sushilkumar, 2015, Int J Hematol Oncol Stem Cell Res, V9, P95eng
hcfmusp.relation.referenceRead J, 2013, AUSTRALAS J DERMATOL, V54, P163, DOI 10.1111/ajd.12013eng
hcfmusp.relation.referenceRichetta AG, 2014, ONCOLOGY-BASEL, V86, P104, DOI 10.1159/000356878eng
hcfmusp.relation.referenceRoorda BD, 2009, CRIT REV ONCOL HEMAT, V69, P187, DOI 10.1016/j.critrevonc.2008.06.004eng
hcfmusp.relation.referenceRusso FP, 2006, GASTROENTEROLOGY, V130, P1807, DOI 10.1053/j.gastro.2006.01.036eng
hcfmusp.relation.referenceSchatton T, 2008, PIGM CELL MELANOMA R, V21, P39, DOI 10.1111/j.1755-148X.2007.00427.xeng
hcfmusp.relation.referenceSchmidt A, 2006, EUR J CELL BIOL, V85, P1179, DOI 10.1016/j.ejcb.2006.05.015eng
hcfmusp.relation.referenceSiegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254eng
hcfmusp.relation.referenceSortino-Rachou AM, 2011, CAD SAUDE PUBLICA, V27, P565, DOI 10.1590/S0102-311X2011000300016eng
hcfmusp.relation.referenceSun B, 2005, STEM CELLS DEV, V14, P292, DOI 10.1089/scd.2005.14.292eng
hcfmusp.relation.referenceTeo AKK, 2010, BIOCHEM J, V428, P11, DOI 10.1042/BJ20100102eng
hcfmusp.relation.referenceTOI M, 1994, JPN J CANCER RES, V85, P1045, DOI 10.1111/j.1349-7006.1994.tb02904.xeng
hcfmusp.relation.referenceUder C, 2018, CYTOM PART A, V93A, P32, DOI 10.1002/cyto.a.23239eng
hcfmusp.relation.referenceYarak S, 2010, AN BRAS DERMATOL, V85, P647, DOI 10.1590/S0365-05962010000500008eng
hcfmusp.relation.referenceZago M.A., 2004, SEMINARIO I FERNANDO, P23eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublicationdfc3734a-a125-4997-9406-5db312e21417
relation.isAuthorOfPublication02795968-5c04-4c21-863d-e11038aba5b8
relation.isAuthorOfPublication.latestForDiscoverydfc3734a-a125-4997-9406-5db312e21417
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_MENEZES_Antitumor_effect_of_cell_therapy_with_mesenchymal_stem_2020.PDF.pdf
Tamanho:
12.25 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/53
Artigos e Materiais de Revistas Científicas - LIM/56
Artigos e Materiais de Revistas Científicas - ODS/03